GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Net Income (Continuing Operations)

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Net Income (Continuing Operations) : $-6.06 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Regencell Bioscience Holdings's Net Income (Continuing Operations) for the six months ended in Jun. 2023 was $-2.75 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2023 was $-6.06 Mil.


Regencell Bioscience Holdings Net Income (Continuing Operations) Historical Data

The historical data trend for Regencell Bioscience Holdings's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Net Income (Continuing Operations) Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Net Income (Continuing Operations)
-0.39 -0.81 -1.35 -7.60 -6.06

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only -1.01 -3.66 -3.94 -3.32 -2.75

Regencell Bioscience Holdings Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings  (NAS:RGC) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Regencell Bioscience Holdings Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus